Pasithea Therapeutics任命首席医疗官

2026-05-04 20:34

Pasithea Therapeutics (KTTA) said on Monday it appointed Kartik Krishnan as chief medical officer as it advances its lead candidate, PAS-004, which is a next-generation MEK inhibitor
Krishnan will oversee clinical strategy and development, with a focus on neurofibromatosis type 1 (NF1)-associated tumors.
“We believe his experience developing cobimetinib, a FDA-approved MEK inhibitor, is particularly relevant to our mission, and that his expertise will directly benefit the progression of our PAS-004 program,” CEO Tiago Reis Marques
Krishnan brings over two decades of experience across clinical development, regulatory strategy, and R&D, with prior roles at OncoNano Medicines, Arcus Biosciences (RCUS), Genentech, and Amgen (AMGN)
Pasithea is currently evaluating PAS-004 in early-stage clinical trials targeting advanced cancers and NF1-related plexiform neurofibromas.

More on Pasithea Therapeutics